NAA11

Across TCGA pan-cancer cohorts, NAA11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAA11 data layer compared with 15 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAA11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NAA11 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NAA11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.275	0.688	<.001	91	view →
CCRCC	OS	Median	III,IV	0.236	0.930	.003	24	view →
LUAD	DFS	Tertile	All	1.000	0.662	.022	8	view →
LSCC	DFS	Tertile	II,III,IV	0.859	0.459	.033	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAA11–PDAC (OS)

Open the PDAC breakdown →